Phase I clinical trials and ex vivo studies conducted by Roche have demonstrated that gantenerumab can safely remove amyloid plaques from the brain of patients with Alzheimer’s disease.

Gantenerumab, an investigational fully human anti-amyloid beta monoclonal antibody will bind to amyloid plaques in the brain and remove them.

The studies also showed that gantenerumab treatment resulted in a dose-dependent reduction of brain amyloid and increase in amyloid load.

Patients are being recruited for a trial to evaluate the efficacy and safety of gantenerumab in patients in the early or prodromal stage of Alzheimer’s disease.

Luca Santarelli, global head of Roche’s neuroscience disease translational area, said that the study objective is not only intended to demonstrate the effects of gantenerumab on brain amyloid, but also to start elucidating its mechanism of action.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.